drugset / Trial / NCT03576820

Intranasal Lidocaine to Treat Pediatric Migraine in the Emergency Department

NCT03576820 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to determine the effect of intranasal lidocaine on pain score in pediatric patients with migraine. Patients with significant pain after oral analgesics and plan for intravenous (IV) abortive therapy will be asked to participate. Half of patients will be given intranasal lidocaine and the other half will be given placebo. Pain scores and associated migraine symptoms (i.e. nausea, vomiting, photophobia, phonophobia, avoidance of activities, and aura) will be monitored and compared between the groups.

Timeline

Start
2018-10-15
Primary completion
2022-12
Completion
2022-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified 20 mg Intranasal

Indications